Myeloma

Simply knowing who to screen, and when, could reduce myeloma-related mortality rates, according to recent research.

When I recited my wedding vows to Eli in 1995, I never expected to be his caregiver. At the time, Eli was seemingly at the peak of good health and in the middle of his nine-year career as a professional linebacker.

The International Myeloma Foundation declared March to be Myeloma Action Month to help raise awareness about the disease.

The definition of smoldering myeloma was reworked in recent years.

Cognitive dysfunction among geriatric patients with blood cancers – such as multiple myeloma, leukemia and lymphoma – is not only prevalent, but may also impact long-term survival.

While recent breakthroughs have led to more treatment options for multiple myeloma, patients are also experiencing new side effects, stressful financial issues and psychological burdens. In turn, recent research found that this increased distress may actually have negative implications for patient outcomes.

Experts focus on genetic abnormalities to advance cancer care.

The annual Los Angeles event was launched 11 years ago in honor of Romano’s Everybody Loves Raymond costar, Peter Boyle, who died of the rare blood cancer multiple myeloma in 2006.

Patients with multiple myeloma who are eligible for stem cell transplantation should still be considered for high-dose therapy (HDT) even in the novel agent era, according to the authors of a study recently published in the Journal of the American Medical Association Oncology.

An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.

These advancements are changing the way many cancers are being treated.

The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).

The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.